SciELO - Scientific Electronic Library Online

vol.61First report of an autochthonous human visceral leishmaniasis in a child from the South of Minas Gerais State, BrazilMurine typhus in Mexico City: report of an imported case author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Revista do Instituto de Medicina Tropical de São Paulo

On-line version ISSN 1678-9946


MUCENIC, Marcos et al. Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review. Rev. Inst. Med. trop. S. Paulo [online]. 2019, vol.61, e12.  Epub Feb 14, 2019. ISSN 1678-9946.

Chronic Hepatitis C relapse after liver transplantation can lead to graft failure within a short time period. The high efficacy and good safety profile of direct-acting antivirals has led to consensual recommendations for using interferon-free treatment after liver transplantation. However, pegylated interferon may still be required for genotype 3 non-responders. We treated a liver graft recipient with grade 1 fibrosis in the biopsy with daclatasvir and sofosbuvir for 12 weeks. He did not respond and progressed to grade 3 fibrosis. Lacking other options, we obtained a sustained virological response with pegylated interferon, ribavirin and sofosbuvir for 12 weeks. The combination of pegylated interferon, ribavirin and sofosbuvir is a viable option after the failure of direct acting antivirals in economically disadvantaged countries.

Keywords : Hepatitis C virus; Liver transplantation; Treatment.

        · text in English     · English ( pdf )